KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today issued the following statement after the conclusion of a meeting of the Anesthetic and Analgesic Drug Products Advisory Committee of the U.S. Food and Drug Administration (FDA) to discuss BRIDION® (sugammadex). BRIDION is the proposed trade name for Merck’s investigational agent for the reversal of neuromuscular blockade (NMB) induced by rocuronium or vecuronium.
Help employers find you! Check out all the jobs and post your resume.
